CytoDyn
VANCOUVER, United States (US) · Health and Medical
Do your work at CytoDyn?
Claim this profile to manage your company.
Verified by Enterprise League
Data quality
Complete · Accuracy
Last verified
May 2026
Overview
CytoDyn is a Vancouver, Washington-based biotechnology company dedicated to developing innovative treatments for solid-tumor oncology and other indications.
We are focused on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor, a protein implicated in a broad range of disease states including cancer metastasis and certain immunological conditions.
Leronlimab’s unique competitive inhibition of the CCR5 receptor offers a paradigm-shifting therapeutic approach, differentiating it from other CCR5 antagonists.
CytoDyn’s commitment is to enhancing the lives of patients through targeted medicine, leveraging the potential of leronlimab across multiple disease areas.
We are focused on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor, a protein implicated in a broad range of disease states including cancer metastasis and certain immunological conditions.
Leronlimab’s unique competitive inhibition of the CCR5 receptor offers a paradigm-shifting therapeutic approach, differentiating it from other CCR5 antagonists.
CytoDyn’s commitment is to enhancing the lives of patients through targeted medicine, leveraging the potential of leronlimab across multiple disease areas.
Contact Details
info@cytodyn.com
VANCOUVER, United States (US)
Company Type
Public Limited Company
Employees
20-30
Categories
Keywords
#cancer
#hiv/aids
#nash
#biotechnology
#pharmaceuticals
Companies teams usually look at after CytoDyn
Comparing a few options usually leads to better decisions
Save companies to compare later. Useful when sharing options with your team
This is how your company profile looks to others.